Details

Autor(en) / Beteiligte

• Sarnak, Mark J.
• Amann, Kerstin
• Bangalore, Sripal
• Cavalcante, João L.
• Charytan, David M.
• Craig, Jonathan C.
• Gill, John S.
• Hlatky, Mark A.
• Jardine, Alan G.
• Landmesser, Ulf
• Newby, L. Kristin
• Herzog, Charles A.
• Cheung, Michael
• Wheeler, David C.
• Winkelmayer, Wolfgang C.
• Marwick, Thomas H.
• Banerjee, Debasish
• Briguori, Carlo
• Chang, Tara I.
• Chen, Chien-Liang
• deFilippi, Christopher R.
• Ding, Xiaoqiang
• Ferro, Charles J.
• Gill, Jagbir
• Gössl, Mario
• Isbel, Nicole M.
• Ishii, Hideki
• Jardine, Meg J.
• Kalra, Philip A.
• Laufer, Günther
• Lentine, Krista L.
• Lobdell, Kevin
• Lok, Charmaine E.
• London, Gérard M.
• Małyszko, Jolanta
• Mark, Patrick B.
• Marwan, Mohamed
• Nie, Yuxin
• Parfrey, Patrick S.
• Pecoits-Filho, Roberto
• Pilmore, Helen
• Qunibi, Wajeh Y.
• Raggi, Paolo
• Rattazzi, Marcello
• Rossignol, Patrick
• Ruturi, Josiah
• Sabanayagam, Charumathi
• Shanahan, Catherine M.
• Shroff, Gautam R.
• Shroff, Rukshana
• Webster, Angela C.
• Weiner, Daniel E.
• Winther, Simon
• Wiseman, Alexander C.
• Yip, Anthony
• Zarbock, Alexander

Titel

Chronic Kidney Disease and Coronary Artery Disease

Ist Teil von

• Journal of the American College of Cardiology, 2019-10, Vol.74 (14), p.1823-1838

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2019

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Chronic kidney disease (CKD) is a major risk factor for coronary artery disease (CAD). As well as their high prevalence of traditional CAD risk factors, such as diabetes and hypertension, persons with CKD are also exposed to other nontraditional, uremia-related cardiovascular disease risk factors, including inflammation, oxidative stress, and abnormal calcium-phosphorus metabolism. CKD and end-stage kidney disease not only increase the risk of CAD, but they also modify its clinical presentation and cardinal symptoms. Management of CAD is complicated in CKD patients, due to their likelihood of comorbid conditions and potential for side effects during interventions. This summary of the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on CAD and CKD (including end-stage kidney disease and transplant recipients) seeks to improve understanding of the epidemiology, pathophysiology, diagnosis, and treatment of CAD in CKD and to identify knowledge gaps, areas of controversy, and priorities for research. [Display omitted] •CKD is associated with very high risk of CAD. CAD management is complicated in CKD patients, due to comorbid conditions and potential side effects during interventions.•There are few trials related to CAD with focus on CKD patients, particularly in those with advanced CKD.•Additional prospective studies focusing on diagnosis, prevention, and treatment of CAD are needed in CKD.